» Articles » PMID: 25232767

Markers of Inflammation in Recipients of Continuous-flow Left Ventricular Assist Devices

Overview
Journal ASAIO J
Specialty General Surgery
Date 2014 Sep 19
PMID 25232767
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Although the newer continuous-flow left ventricular assist devices (CF-LVADs) provide clinical advantages over the pulsatile pumps, the effects of low pulsatility on inflammation are incompletely understood. The objective of our study was to examine the levels of inflammatory mediators in CF-LVAD recipients compared with both healthy control subjects and heart failure patients who were candidates for CF-LVAD support. Plasma levels of chemokines, cytokines, and inflammatory markers were measured in 18 CF-LVAD recipients and compared with those of 14 healthy control subjects and 14 heart failure patients who were candidates for CF-LVADs. The levels of granulocyte macrophage-colony stimulating factor, macrophage inflammatory proteins-1β, and macrophage-derived chemokine were significantly higher in the CF-LVAD group compared with both the heart failure and the healthy control groups, whereas no significant differences were observed between the healthy control subjects and the heart failure groups. Compared with the healthy controls, C-reactive protein, interferon gamma-induced protein-10, monocyte chemotactic protein-1, and interleukin-8 levels were significantly higher in both the CF-LVAD and heart failure groups, but no significant differences were observed between the CF-LVAD recipients and the heart failure patients. Inflammatory markers were elevated in CF-LVAD recipients compared with healthy control subjects and the heart failure patients. Further studies should investigate the clinical implications of elevated levels of inflammation in CF-LVAD recipients.

Citing Articles

Iron Deficiency in Patients with Left Ventricular Assist Devices.

Nielsen W, Gustafsson F Card Fail Rev. 2024; 10:e08.

PMID: 39144580 PMC: 11322955. DOI: 10.15420/cfr.2023.26.


Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device.

Galeone A, Buccoliero C, Barile B, Nicchia G, Onorati F, Luciani G Int J Mol Sci. 2024; 25(1).

PMID: 38203459 PMC: 10779015. DOI: 10.3390/ijms25010288.


Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts.

Nascimbene A, Bark D, Smadja D Blood. 2023; 143(8):661-672.

PMID: 37890145 PMC: 10900168. DOI: 10.1182/blood.2022018096.


Depression among Patients with an Implanted Left Ventricular Assist Device: Uncovering Pathophysiological Mechanisms and Implications for Patient Care.

Alnsasra H, Khalil F, Perue R, Azab A Int J Mol Sci. 2023; 24(14).

PMID: 37511030 PMC: 10379142. DOI: 10.3390/ijms241411270.


Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice.

Khalil F, Asleh R, Perue R, Weinstein J, Solomon A, Betesh-Abay B Biomedicines. 2023; 11(3).

PMID: 36979735 PMC: 10045906. DOI: 10.3390/biomedicines11030757.